Get started
Author

Ornella Ponzoni

Management of PALB2 ‐associated breast cancer: A literature review and case report
2023 · Angela Toss, Ornella Ponzoni, et al. · Clinical Case Reports · 14
PDF
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes
2025 · Claudia Omarini, Virginia Catani, et al. · Biomarker Research · 13
PDF
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study
2024 · Fabio Canino, Monica Barbolini, et al. · BMC Cancer · 9
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer
2025 · Emma Zattarin, Antonio Marra, et al. · npj Breast Cancer · 6
PDF
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients
2024 · Fabio Canino, Antonio Tornincasa, et al. · International Journal of Molecular Sciences · 6
PDF
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer
2024 · Elisa D'Agostino, Luciana Mastrodomenico, et al. · Cancer Treatment Reviews · 4
Chemoprevention strategies in hereditary breast and ovarian cancer syndromes
2024 · Elena Barbieri, Marta Venturelli, et al. · Tumori Journal · 3
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2
2026 · Giacomo Mazzoli, Leonardo Provenzano, et al. · The Breast · 2
PDF
PARPi effectiveness after CDK4/6i in BRCA1 - and BRCA2 -associated HR+/HER2- advanced breast cancer: Results from the multicenter real-world PAMBRACA study.
2025 · Emma Zattarin, Antonio Marra, et al. · Journal of Clinical Oncology · 2
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study
2026 · Francesca Ligorio, Leonardo Provenzano, et al. · The Breast · 1
Clinical implications of the type and genomic location of pathogenic BRCA1 and BRCA2 variants in hereditary breast and ovarian cancer
2026 · Emma Zattarin, Claudia Piombino, et al. · Critical Reviews in Oncology/Hematology
Prognostic value of hormone receptor expression in patients with HR+/HER2− advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study
2026 · Francesca Ligorio, Leonardo Provenzano, et al. · EClinicalMedicine
Clinicopathologic features and prognosis of breast cancer in germline ATM and CHEK2 carriers: A monocentric retrospective study.
2026 · Flavia Siciliano, Emma Zattarin, et al. · Journal of Clinical Oncology
Abstract PS1-11-28: Prognostic impact of type and location of germline BRCA2 pathogenic or likely pathogenic variants in patients with HR+/HER2- advanced breast cancer: results from the multicenter real-world PAMBRACA study
2026 · E. Zattarin, E. Tenedini, et al. · Clinical Cancer Research
Future directions for antibody-drug conjugates in urothelial cancer
2025 · Elisa D’Agostino, Marta Pirola, et al. · Expert Review of Anticancer Therapy
Works count: 20
Citation count: 60
H-index: 5
I10-index: 2
Year
Topic
Type